Company Filing History:
Years Active: 2020
Title: Evgeny Kiselev: Innovator in Pharmaceutical Chemistry
Introduction
Evgeny Kiselev is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptors in the body.
Latest Patents
Kiselev holds a patent for "Triazole derivatives as P2Y receptor antagonists." This patent describes compounds that act as antagonists of the P2Y receptor, including a compound of formula (I) with specific structural characteristics. The patent also details dendron conjugates comprising these compounds and outlines methods for using them to treat various disorders. These disorders include inflammation, diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, conditions associated with metabolic syndrome, and asthma. Additionally, it describes methods for antagonizing P2 receptor activity in a cell.
Career Highlights
Evgeny Kiselev is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to focus on innovative research that has the potential to impact public health significantly.
Collaborations
Kiselev has collaborated with esteemed colleagues, including Kenneth Alan Jacobson and Anna Junker. These collaborations have likely enriched his research and contributed to the advancement of his projects.
Conclusion
Evgeny Kiselev's work exemplifies the intersection of innovation and healthcare, showcasing how targeted compounds can lead to advancements in treating various medical conditions. His contributions to pharmaceutical chemistry are noteworthy and continue to influence the field.